Table 5.
Risk for coronavirus disease 2019-related mortality
| Covariate |
Univariate analyses
|
Multivariate analyses
|
||||
|
HR
|
95%CI
|
P value
|
HR
|
95%CI
|
P value
|
|
| ICU admission | 25.5 | 8.26-78.8 | < 0.001 | 27.2 | 8.69-84.9 | < 0.001 |
| Age at SARS-CoV-2 infection diagnosis (per year) | 1.04 | 0.99-1.07 | 0.06 | 1.04 | 1.0-1.08 | 0.04 |
| Male recipient | 1.75 | 0.66-4.59 | 0.26 | |||
| Nonwhite recipient | 0.54 | 0.16-1.85 | 0.33 | |||
| Diabetes as a cause of ESKD vs other | 0.66 | 0.22-1.99 | 0.46 | |||
| Living donor recipient | 0.68 | 0.25-1.90 | 0.47 | |||
| Previous transplant | 0.48 | 0.14-1.66 | 0.25 | |||
| Tacrolimus + MPA + prednisone maintenance vs other | 1.33 | 0.44-4.02 | 0.61 | |||
| Prednisone based immunosuppression | 0.52 | 0.15-1.77 | 0.30 | |||
| Treatment of rejection before SARS-CoV-2 infection | -- | -- | -- | |||
| Vaccinated | 0.66 | 0.26-1.60 | 0.35 | |||
| Baseline eGFR (per mL/m2) | 1.01 | 0.99-1.03 | 0.27 | |||
| Interval from transplant to SARS-CoV-2 infection (per month) | 1.0 | 0.99-1.01 | 0.68 | |||
| Respiratory symptoms for hospital admission | 1.13 | 0.43-2.99 | 0.80 | |||
| Remdesivir for management of COVID | 0.62 | 0.21-1.88 | 0.40 | |||
COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; eGFR: Estimated glomerular filtration rate; ICU: Intensive care unit; ESKD: End-stage kidney disease; MPA: Mycophenolic acid.